A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered BW-50218 in Healthy Participants
Latest Information Update: 16 Feb 2026
At a glance
- Drugs BW 50218 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Argo Biopharma
Most Recent Events
- 16 Feb 2026 New trial record